Equities analysts expect that Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $1.17 for the current fiscal quarter, Zacks reports. Ten analysts have made estimates for Edwards Lifesciences’ earnings, with the lowest EPS estimate coming in at $1.15 and the highest estimate coming in at $1.19. Edwards Lifesciences posted earnings of $0.94 per share during the same quarter last year, which would indicate a positive year over year growth rate of 24.5%. The business is expected to announce its next quarterly earnings results after the market closes on Thursday, January 31st.
According to Zacks, analysts expect that Edwards Lifesciences will report full year earnings of $4.70 per share for the current fiscal year, with EPS estimates ranging from $4.68 to $4.71. For the next year, analysts forecast that the business will post earnings of $5.21 per share, with EPS estimates ranging from $5.15 to $5.25. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business had revenue of $906.60 million during the quarter, compared to analyst estimates of $927.56 million. During the same period in the previous year, the business posted $0.84 EPS. The company’s quarterly revenue was up 10.4% on a year-over-year basis.
Shares of NYSE EW traded down $0.12 during midday trading on Thursday, hitting $168.29. The company’s stock had a trading volume of 1,470,298 shares, compared to its average volume of 1,222,863. Edwards Lifesciences has a 1-year low of $121.40 and a 1-year high of $175.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. The firm has a market capitalization of $35.21 billion, a PE ratio of 44.29, a price-to-earnings-growth ratio of 2.01 and a beta of 0.90.
In other news, VP Catherine M. Szyman sold 700 shares of the business’s stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $155.00, for a total value of $108,500.00. Following the completion of the sale, the vice president now directly owns 24,482 shares in the company, valued at $3,794,710. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the business’s stock in a transaction on Wednesday, December 12th. The stock was sold at an average price of $164.99, for a total transaction of $907,445.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 221,272 shares of company stock worth $32,781,593. 1.84% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of EW. Capital Research Global Investors raised its stake in Edwards Lifesciences by 164.8% during the 3rd quarter. Capital Research Global Investors now owns 3,545,266 shares of the medical research company’s stock valued at $617,231,000 after purchasing an additional 2,206,539 shares during the last quarter. FMR LLC increased its holdings in Edwards Lifesciences by 32.9% in the 2nd quarter. FMR LLC now owns 6,714,684 shares of the medical research company’s stock valued at $977,456,000 after buying an additional 1,663,511 shares during the period. Janus Henderson Group PLC increased its holdings in Edwards Lifesciences by 117.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,505,128 shares of the medical research company’s stock valued at $436,144,000 after buying an additional 1,350,879 shares during the period. MERIAN GLOBAL INVESTORS UK Ltd increased its holdings in Edwards Lifesciences by 211.7% in the 3rd quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 1,049,182 shares of the medical research company’s stock valued at $182,662,000 after buying an additional 712,537 shares during the period. Finally, Jennison Associates LLC increased its holdings in Edwards Lifesciences by 70.8% in the 3rd quarter. Jennison Associates LLC now owns 1,444,384 shares of the medical research company’s stock valued at $251,467,000 after buying an additional 598,735 shares during the period. Institutional investors and hedge funds own 82.42% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Read More: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.